January 20, 2014, NewBio Therapeutics, Inc. (NBT), a biotechnology company that develops antibody drug conjugate (ADC) products using its proprietary linker-drug technology, today announced that NBT 828 project is under an agreement with Genor Biopharm that grants NewBio Therapeutics exclusive rights to use the company’s GB221 monoclonal antibody to develop ADC anticancer therapeutics that target Her2 overexpressing breast cancer. Under this agreement, NewBio Therapeutics is entitled to receive front payment and milestone payments potentially totaling up to $6.25 (3750/6 RMB) million for each resulting product plus royalties on sales.
NBT828 consists of a GB221 antibody that targets Her2 with cancer-cell killing agent attached using one of NBT’s proprietary linkers and conjugation technology. In preclinical testing, NBT809 (GB221-vcMMAE) demonstrated potent, targeted anticancer activity against Her2-expressing tumors.
January 20, 2014, NewBio Therapeutics, Inc. (NBT), a biotechnology company that develops antibody drug conjugate (ADC) products using its proprietary linker-drug technology, today announced that NBT 828 project is under an agreement with Genor Biopharm that grants NewBio Therapeutics exclusive rights to use the company’s GB221 monoclonal antibody to develop ADC anticancer therapeutics that target Her2 overexpressing breast cancer. Under this agreement, NewBio Therapeutics is entitled to receive front payment and milestone payments potentially totaling up to $6.25 (3750/6 RMB) million for each resulting product plus royalties on sales.
NBT828 consists of a GB221 antibody that targets Her2 with cancer-cell killing agent attached using one of NBT’s proprietary linkers and conjugation technology. In preclinical testing, NBT809 (GB221-vcMMAE) demonstrated potent, targeted anticancer activity against Her2-expressing tumors.